Does the media refer more to BNTX or COGT?

In the previous week, BioNTech had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for BioNTech and 2 mentions for Cogent Biosciences. BioNTech's average media sentiment score of 0.89 beat Cogent Biosciences' score of 0.25 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COGT or ROIV?

In the previous week, Roivant Sciences had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for Roivant Sciences and 2 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 0.56 beat Cogent Biosciences' score of 0.25 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 9 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INSM or COGT more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Cogent Biosciences' return on equity of -104.27% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Cogent Biosciences N/A -104.27% -54.64%

Does the media prefer INSM or COGT?

In the previous week, Insmed had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Insmed and 2 mentions for Cogent Biosciences. Insmed's average media sentiment score of 1.36 beat Cogent Biosciences' score of 0.25 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VTRS or COGT more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Cogent Biosciences N/A -104.27% -54.64%

Does the media refer more to VTRS or COGT?

In the previous week, Viatris had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Cogent Biosciences. Viatris' average media sentiment score of 0.72 beat Cogent Biosciences' score of 0.25 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer COGT or GMAB?

In the previous week, Genmab A/S had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Genmab A/S and 2 mentions for Cogent Biosciences. Genmab A/S's average media sentiment score of 0.69 beat Cogent Biosciences' score of 0.25 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cogent Biosciences (COGT) Competitors

$38.69 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$37.90 -0.79 (-2.04%)

As of 07/2/2026 07:41 PM Eastern

Compare

COGT vs. BNTX, ROIV, INSM, VTRS, and GMAB

Should you buy Cogent Biosciences stock or one of its competitors? MarketBeat compares Cogent Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cogent Biosciences include BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Cogent Biosciences compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cogent Biosciences has lower revenue, but higher earnings than BioNTech. Cogent Biosciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.60	-$1.29B	-$5.88	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Cogent Biosciences has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Cogent Biosciences	N/A	-104.27%	-54.64%

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

In the previous week, BioNTech had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for BioNTech and 2 mentions for Cogent Biosciences. BioNTech's average media sentiment score of 0.89 beat Cogent Biosciences' score of 0.25 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech currently has a consensus target price of $129.56, suggesting a potential upside of 32.83%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 13.02%. Given BioNTech's higher possible upside, research analysts clearly believe BioNTech is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

BioNTech beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Roivant Sciences?

Cogent Biosciences (NASDAQ:COGT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Cogent Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Cogent Biosciences presently has a consensus price target of $43.73, suggesting a potential upside of 13.02%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential downside of 4.38%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has higher revenue and earnings than Cogent Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Roivant Sciences	$8.26M	3,059.07	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 16 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for Roivant Sciences and 2 mentions for Cogent Biosciences. Roivant Sciences' average media sentiment score of 0.56 beat Cogent Biosciences' score of 0.25 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	9 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.8% of Roivant Sciences shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Summary

Roivant Sciences beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Insmed?

Insmed (NASDAQ:INSM) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Cogent Biosciences has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.89	-$1.28B	-$5.75	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Insmed had 6 more articles in the media than Cogent Biosciences. MarketBeat recorded 8 mentions for Insmed and 2 mentions for Cogent Biosciences. Insmed's average media sentiment score of 1.36 beat Cogent Biosciences' score of 0.25 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 89.84%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 13.02%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Cogent Biosciences' return on equity of -104.27% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Insmed beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

How does Cogent Biosciences compare to Viatris?

Viatris (NASDAQ:VTRS) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Cogent Biosciences has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.26	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Viatris had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Cogent Biosciences. Viatris' average media sentiment score of 0.72 beat Cogent Biosciences' score of 0.25 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viatris has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

79.9% of Viatris shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Cogent Biosciences	N/A	-104.27%	-54.64%

Viatris presently has a consensus price target of $17.50, suggesting a potential upside of 4.79%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 13.02%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Viatris and Cogent Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Genmab A/S?

Cogent Biosciences (NASDAQ:COGT) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

7.1% of Genmab A/S shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Genmab A/S had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Genmab A/S and 2 mentions for Cogent Biosciences. Genmab A/S's average media sentiment score of 0.69 beat Cogent Biosciences' score of 0.25 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences currently has a consensus target price of $43.73, indicating a potential upside of 13.02%. Genmab A/S has a consensus target price of $38.21, indicating a potential upside of 34.04%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60

Genmab A/S has a net margin of 21.05% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Cogent Biosciences on 12 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.61B	$3.78B	$7.19B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	-17.83	21.43	27.99	24.69
Price / Sales	N/A	325.99	534.82	99.67
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	10.08	8.66	10.96	6.46
Net Income	-$328.94M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.51%	3.39%	2.12%	1.69%
1 Month Performance	24.73%	10.81%	5.25%	3.81%
1 Year Performance	408.08%	62.61%	33.29%	23.90%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	1.5727 of 5 stars	$38.69 flat	$43.73 +13.0%	+408.1%	$6.61B	N/A	N/A	80
BNTX BioNTech	3.8099 of 5 stars	$90.19 -0.8%	$129.56 +43.7%	-11.0%	$22.98B	$3.25B	N/A	7,807	News Coverage Gap Down
ROIV Roivant Sciences	1.8227 of 5 stars	$31.25 -0.6%	$33.59 +7.5%	+223.9%	$22.61B	$8.26M	N/A	860	Insider Trade
INSM Insmed	3.6703 of 5 stars	$98.61 +2.9%	$211.86 +114.9%	+13.3%	$20.76B	$606.42M	N/A	1,664	Positive News Gap Down
VTRS Viatris	2.7662 of 5 stars	$15.38 +0.1%	$17.50 +13.8%	+80.5%	$17.90B	$14.30B	N/A	30,000	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. BNTX, ROIV, INSM, VTRS, and GMAB

How does Cogent Biosciences compare to BioNTech?

Summary

How does Cogent Biosciences compare to Roivant Sciences?

Summary

How does Cogent Biosciences compare to Insmed?

Summary

How does Cogent Biosciences compare to Viatris?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. BNTX, ROIV, INSM, VTRS, and GMAB

How does Cogent Biosciences compare to BioNTech?

Do insiders and institutionals have more ownership in BNTX or COGT?

Which has higher valuation and earnings, BNTX or COGT?

Is BNTX or COGT more profitable?

Which has more risk and volatility, BNTX or COGT?

Does the media refer more to BNTX or COGT?

Do analysts recommend BNTX or COGT?

Summary

How does Cogent Biosciences compare to Roivant Sciences?

Is COGT or ROIV more profitable?

Do analysts recommend COGT or ROIV?

Which has preferable earnings & valuation, COGT or ROIV?

Does the media refer more to COGT or ROIV?

Do insiders & institutionals have more ownership in COGT or ROIV?

Which has more volatility and risk, COGT or ROIV?

Summary

How does Cogent Biosciences compare to Insmed?

Which has higher earnings and valuation, INSM or COGT?

Does the media prefer INSM or COGT?

Do analysts recommend INSM or COGT?

Which has more volatility and risk, INSM or COGT?

Is INSM or COGT more profitable?

Summary

How does Cogent Biosciences compare to Viatris?

Which has stronger valuation & earnings, VTRS or COGT?

Does the media refer more to VTRS or COGT?

Which has more risk & volatility, VTRS or COGT?

Do institutionals & insiders hold more shares of VTRS or COGT?

Is VTRS or COGT more profitable?

Do analysts rate VTRS or COGT?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Do insiders & institutionals believe in COGT or GMAB?

Does the media prefer COGT or GMAB?

Do analysts recommend COGT or GMAB?

Which has more volatility and risk, COGT or GMAB?

Which has higher valuation & earnings, COGT or GMAB?

Is COGT or GMAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools